Horizon Therapeutics

Horizon Therapeutics

Horizon Therapeutics was originally founded in 2008 as a biopharmaceutical company focused on rare and autoimmune diseases. After its acquisition by Amgen in October 2023, the entity transitioned into a family office structure based in Dublin, Ireland. The wealth originates from the sale of the company to Amgen. The investment strategy of this entity is not publicly detailed, but it is presumed to manage the proceeds from the Amgen transaction. As a family office, it likely allocates capital across public equities, private investments, and direct holdings in healthcare and biotech. No specific portfolio companies or co-investments have been disclosed. The scale of the entity is not publicly disclosed. No team size, additional offices, or adjacent vehicles like charitable foundations have been identified. The recent activity includes the completion of the Amgen acquisition in October 2023 (per public record). A key structural differentiator is the entity's origin as a publicly traded company that became a family office post-acquisition — a model more common in biotech where founders or management retain capital from a sale. This structure allows direct control over the remaining capital without external shareholder obligations. Succession and governance details are not publicly available.